Announced details
BNCT; pharmaceuticals; medical care; head and neck cancer
BNCT for patients with head and neck cancer began in March 2026 (cumulative number of patients: Not disclosed)
We have entered into a collaboration agreement with CBSH and Pengbo covering the development and post-approval sales rollout of our pharmaceutical product for BNCT in mainland China. We are collaborating with SUMITOMO HEAVY INDUSTRIES,LTD. on BNCT information and promotion activities at the CIIE.
CBSH has Hong Kong Stock Exchange Stock Code: 8037. Pengbo is a CBSH subsidiary that operates a BNCT center in the Bo'ao Lecheng International Medical Tourism Pilot Zone in Hainan, China. No other overview of SUMITOMO HEAVY INDUSTRIES,LTD. is provided.
National Exhibition and Convention Center (Shanghai), Shanghai, China; Bo'ao Lecheng International Medical Tourism Pilot Zone, Hainan, China (Hainan Island medical special zone)
The policy is to promote BNCT in mainland China and support the expansion of our business. The specific impact on financial results is Not disclosed
The company does not address Contract Value / Offering price.
Official CIIE website; Ministry of Commerce of the People's Republic of China and Shanghai Municipal People's Government (CIIE organizers)
| Item | Details |
|---|---|
| Names of Products / Services Covered | BNCT (boron neutron capture therapy); our pharmaceutical product for BNCT |
| Counterparty | China Biotech Services Holdings Limited (CBSH; Hong Kong Stock Exchange Stock Code: 8037); Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd. (Pengbo); SUMITOMO HEAVY INDUSTRIES,LTD. |
| Counterparty overview | CBSH has Hong Kong Stock Exchange Stock Code: 8037. Pengbo is a CBSH subsidiary that operates a BNCT center in the Bo'ao Lecheng International Medical Tourism Pilot Zone in Hainan, China. No other overview of SUMITOMO HEAVY INDUSTRIES,LTD. is provided. |
| Relationship with the Company | We have entered into a collaboration agreement with CBSH and Pengbo covering the development and post-approval sales rollout of our pharmaceutical product for BNCT in mainland China. We are collaborating with SUMITOMO HEAVY INDUSTRIES,LTD. on BNCT information and promotion activities at the CIIE. |
| Contract Date | Master Collaboration Agreement announced on 12 August 2026. The date on which the agreement was executed itself is Not disclosed |
| Launch date | 5 to 10 November 2026 (scheduled): CIIE and BNCT promotion activities. BNCT at the BNCT center operated by Pengbo has been underway since March 2026 |
| Applicable area | BNCT; pharmaceuticals; medical care; head and neck cancer |
| Location | National Exhibition and Convention Center (Shanghai), Shanghai, China; Bo'ao Lecheng International Medical Tourism Pilot Zone, Hainan, China (Hainan Island medical special zone) |
| Usage history | BNCT for patients with head and neck cancer began in March 2026 (cumulative number of patients: Not disclosed) |
| Impact on Business Performance | The policy is to promote BNCT in mainland China and support the expansion of our business. The specific impact on financial results is Not disclosed |
| Source | Official CIIE website; Ministry of Commerce of the People's Republic of China and Shanghai Municipal People's Government (CIIE organizers) |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This initiative is intended to raise awareness of BNCT in China and strengthen collaboration with relevant organizations, thereby promoting BNCT in mainland China and supporting the expansion of our business.